- Home
- PLD vs VRTX Comparison
PLD vs VRTX Comparison
Compare PLD & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLD
- VRTX
- Stock Information
- Founded
- PLD 1983
- VRTX 1989
- Country
- PLD United States
- VRTX United States
- Employees
- PLD N/A
- VRTX N/A
- Industry
- PLD Real Estate Investment Trusts
- VRTX EDP Services
- Sector
- PLD Real Estate
- VRTX Technology
- Exchange
- PLD Nasdaq
- VRTX Nasdaq
- Market Cap
- PLD 111.3B
- VRTX 128.5B
- IPO Year
- PLD 1994
- VRTX 1991
- Fundamental
- Price
- PLD $115.79
- VRTX $450.97
- Analyst Decision
- PLD Buy
- VRTX Buy
- Analyst Count
- PLD 18
- VRTX 29
- Target Price
- PLD $131.39
- VRTX $513.58
- AVG Volume (30 Days)
- PLD 3.4M
- VRTX 1.4M
- Earning Date
- PLD 01-15-2025
- VRTX 11-04-2024
- Dividend Yield
- PLD 3.32%
- VRTX N/A
- EPS Growth
- PLD 2.06
- VRTX N/A
- EPS
- PLD 3.31
- VRTX N/A
- Revenue
- PLD $8,239,209,999.00
- VRTX $10,625,800,000.00
- Revenue This Year
- PLD N/A
- VRTX $12.20
- Revenue Next Year
- PLD $7.18
- VRTX $8.31
- P/E Ratio
- PLD $34.97
- VRTX N/A
- Revenue Growth
- PLD 0.81
- VRTX 10.06
- 52 Week Low
- PLD $101.11
- VRTX $346.29
- 52 Week High
- PLD $137.52
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- PLD 48.45
- VRTX 38.12
- Support Level
- PLD $112.41
- VRTX $445.00
- Resistance Level
- PLD $115.44
- VRTX $519.88
- Average True Range (ATR)
- PLD 2.31
- VRTX 15.37
- MACD
- PLD 0.41
- VRTX -5.29
- Stochastic Oscillator
- PLD 76.48
- VRTX 7.97
About PLD Prologis Inc.
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1.2 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $60 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.